JMI Laboratories, North Liberty, Iowa, USA.
Antimicrob Agents Chemother. 2012 Mar;56(3):1619-23. doi: 10.1128/AAC.05789-11. Epub 2012 Jan 9.
BC-3781 is a novel semisynthetic pleuromutilin antimicrobial agent developed as an intravenous and oral therapy for acute bacterial skin and skin structure infections (ABSSSI) and respiratory tract infections (RTI). BC-3781 and comparator agents were tested by the broth microdilution method against 1,893 clinical Gram-positive organisms predominantly causing ABSSSI. BC-3781 exhibited potent activity against methicillin-resistant Staphylococcus aureus (MIC(50/90), 0.12/0.25 μg/ml), coagulase-negative staphylococci (MIC(50/90), 0.06/0.12 μg/ml), β-hemolytic streptococci (MIC(50/90), 0.03/0.06 μg/ml), viridans group streptococci (MIC(50/90), 0.12/0.5 μg/ml), and Enterococcus faecium (including vancomycin-nonsusceptible strains) (MIC(50/90), 0.12/2 μg/ml). Compared with other antibiotics in use for the treatment of ABSSSI, BC-3781 displayed the lowest MICs and only a minimal potential for cross-resistance with other antimicrobial classes.
BC-3781 是一种新型半合成截短侧耳素类抗菌药物，开发用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）和呼吸道感染（RTI）的静脉内和口服治疗药物。BC-3781 和对照药物通过肉汤微量稀释法对 1893 种主要引起 ABSSSI 的临床革兰氏阳性菌进行了测试。BC-3781 对耐甲氧西林金黄色葡萄球菌（MIC（50/90），0.12/0.25μg/ml）、凝固酶阴性葡萄球菌（MIC（50/90），0.06/0.12μg/ml）、β-溶血性链球菌（MIC（50/90），0.03/0.06μg/ml）、草绿色链球菌（MIC（50/90），0.12/0.5μg/ml）和屎肠球菌（包括万古霉素耐药株）（MIC（50/90），0.12/2μg/ml）具有强大的活性。与用于治疗 ABSSSI 的其他抗生素相比，BC-3781 显示出最低的 MIC 值，并且与其他抗菌药物类别仅具有最小的交叉耐药潜力。
